Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population

Marius M. Hoeper (Hannover, Germany), Marius Hoeper, Nazzareno Galie, Joan Albert Barbera, Adaani Frost, Ardeschir Ghofrani, Valerie McLaughlin, Andrew Peacock, Gerald Simonneau, Jean-Luc Vachiery, Christiana Blair, Hunter Gillies, Julia Harris, Jon Langley, Lewis Rubin

Source: International Congress 2015 – Pulmonary hypertension: new treatment insights

Session: Pulmonary hypertension: new treatment insights
Session type: Oral Presentation
Number: 4994

Disease area: Pulmonary vascular diseases

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Marius M. Hoeper (Hannover, Germany), Marius Hoeper, Nazzareno Galie, Joan Albert Barbera, Adaani Frost, Ardeschir Ghofrani, Valerie McLaughlin, Andrew Peacock, Gerald Simonneau, Jean-Luc Vachiery, Christiana Blair, Hunter Gillies, Julia Harris, Jon Langley, Lewis Rubin. Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population. Eur Respir J 2015; 46: Suppl. 59, 4994

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013
Rationale and study design of the RESPITE trial: Riociguat clinical effects studied in pulmonary arterial hypertension (PAH) patients with insufficient treatment response to PDE-5 inhibitors (PDE-5i) Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015
Rapid switch from epoprostenol (EPO) to intravenous treprostinil (TRE) in patients with pulmonary arterial hypertension (PAH): safety, efficacy, and treatment satisfaction Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005
A clinical comparison of slow- and rapid-escalation treprostinil dosing regimens in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 563s Year: 2003
Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015
Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015
Exercise tolerability in children with pulmonary arterial hypertension (PAH), a population pk/pd assessment of the effects of sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009
Effect of riociguat on pulmonary arterial compliance (PAC) in patients with CTEPH in the CHEST-1 study Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015
Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010
Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012
Safety of long-term sildenafil 20 or 80 mg TID in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010
LTI-201: Evaluation of the hemodynamics and safety of inhaled LIQ861 (treprostinil) in pulmonary arterial hypertension (WHO Group 1) patients Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020
Clinical sildenafil use in Belgian patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2) Source: Eur Respir J 2015; 45: 1303-1313 Year: 2015
A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011
Survival with first-line bosentan in patients with primary pulmonary hypertension. Source: Eur Respir J 2005; 25: 942 Year: 2005
Population pharmacokinetic (PK) of sildenafil in paediatric and adult pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009